Pharmacological Inhibition of PP2A Overcomes Nab-Paclitaxel Resistance by Downregulating MCL1 in Esophageal Squamous Cell Carcinoma (ESCC)

SIMPLE SUMMARY: Paclitaxel-based chemotherapy has been introduced to treat esophageal squamous cell carcinoma. While its initial efficacy has been clinically established, the development of resistance is inevitable. To understand the paclitaxel resistance mechanism, we developed nanoparticle albumin...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Qi, Wang, Herui, Jiang, Dongxian, Xu, Chen, Cui, Jing, Zhang, Qi, Wang, Haixing, Huang, Jie, Su, Jieakesu, Wu, Gen Sheng, Zhuang, Zhengping, Hou, Yingyong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8507542/
https://www.ncbi.nlm.nih.gov/pubmed/34638252
http://dx.doi.org/10.3390/cancers13194766

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8507542/
https://www.ncbi.nlm.nih.gov/pubmed/34638252
http://dx.doi.org/10.3390/cancers13194766

Ejemplares similares